Guangdong South New Media Co Ltd (300770 SHE) stock market data APIs
¥40.7117
0.31(0.8%)
as of July 11, 2025
Try our APIs with
free plan!
Guangdong South New Media Co Ltd Financial Data Overview
Price chart is built with
Anychart
Guangdong Southern New Media Co.,Ltd. provides IPTV, internet audio-visual, and content copyright services in China. The company offers video, music, education, games, life, and other various content and related services. It also provides internet mainstream media channels, such as TV and cable TV services, as well as audio-visual value-added services to household users. Guangdong Southern New Media Co.,Ltd. was founded in 2010 and is headquartered in Guangzhou, China.
Prev. Close
40.7117
Open
41.0209
High
41.3002
Low
40.3276
52 wk Range
28.5066-45.6732
Market Cap
9 387 M
P/E Ratio
14.0308
Shares Outstanding
229 M
Revenue
1 585 M
EPS
0.7023
Dividends (Yield)
0.039
Beta
0.356
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Guangdong South New Media Co Ltd data using free add-ons & libraries
Get Guangdong South New Media Co Ltd Fundamental Data
Guangdong South New Media Co Ltd Fundamental data includes:
- Net Revenue: 1 585 M
- EBITDA: 660 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Guangdong South New Media Co Ltd News
New
Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities
-- Clinical data from Phase 2 Basket Study including five cohorts totaling 65 patients demonstrated proof-of-concept in HET POMC, PCSK1 or LEPR deficiencies, SRC1 and SH2B1 deficiency obesities – -...
Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities
-- Clinical data from Phase 2 Basket Study including five cohorts totaling 65 patients demonstrated proof-of-concept in HET POMC, PCSK1 or LEPR deficiencies, SRC1 and SH2B1 deficiency obesities – -...
Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts
BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic di...
Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts
BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic di...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
